Sonnet BioTherapeutics Holdings, Inc. Logo

Sonnet BioTherapeutics Holdings, Inc.

Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.

SONN | US

Overview

Corporate Details

ISIN(s):
US83548R1059
LEI:
Country:
United States of America
Address:
100 OVERLOOK CENTER, 8540 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company that develops targeted biologic medicines. The company's core technology is its proprietary Fully Human Albumin-Binding (FHAB™) platform, which utilizes a single-chain antibody fragment (scFv) that binds to the body's own albumin. This 'hitch-hiking' mechanism is designed to deliver cytokine payloads directly to tumor tissues, enhancing drug penetration, retention, and local activation. Sonnet's therapeutic goal is to convert immunologically 'cold' tumors into 'hot' tumors, thereby making them more responsive to treatment. The company's pipeline consists of several cytokine-derived therapeutic candidates in clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sonnet BioTherapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sonnet BioTherapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sonnet BioTherapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France
ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.